Stifel resumed coverage of Janux Therapeutics (JANX) with a Buy rating and $45 price target The firm views the development of T cell engagers for solid tumor applications as a “relevant trend” within oncology. Janux’s TRACTr platform “meaningfully expands” the universe of targetable antigens, the analyst tells investors in a research note. Stifel expects a year-end update to improve visibility into the profile of JANX00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JANX:
- Janux Therapeutics initiated with a Buy at Guggenheim
- Piper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potential
- Janux Therapeutics initiated with an Overweight at Piper Sandler
- Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations
- Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials